ReviewJournal of ovarian research2017
Circulating cell-free DNA and circulating tumor cells, the "liquid biopsies" in ovarian cancer.
Review in Journal of ovarian research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 75 citations in OpenAlex.
- Diagnosis and monitoring of breast cancer with a novel circulating tumor cells enrichment device.Biomarkers in medicine · 2025Article
- The Role of Circulating Tumor DNA in Ovarian Cancer.Cancers · 2024Review
- The Impact of Liquid Biopsy in Advanced Ovarian Cancer Care.Diagnostics (Basel, Switzerland) · 2024Article
- Liquid biopsy in T-cell lymphoma: biomarker detection techniques and clinical application.Molecular cancer · 2024Review
- Screening and identification of serum exosomal protein ZNF587B in liquid biopsy for ovarian cancer diagnosis.American journal of cancer research · 2024Article
- Depth of invasion to the bladder wall as a prognostic factor and its association with circulating cell-free DNA levels in patients with muscle-invasive bladder cancer.Current urology · 2023Article
- Circulating Tumor DNA from Ascites as an alternative to tumor sampling for genomic profiling in ovarian cancer patients.Biomarker research · 2023Article
- Microfluidics engineering towards personalized oncology-a review.In vitro models · 2023Review
- Through the Looking Glass: Updated Insights on Ovarian Cancer Diagnostics.Diagnostics (Basel, Switzerland) · 2023Review
- Role of Exosomes in the Invasion and Metastasis of Ovarian Cancer and Application Potential of Clinical Diagnosis and Treatment.Journal of Cancer · 2023Review
- Review
- Circulating Cell Free DNA and DNA Integrity Index as Discriminating Tools between Breast Cancer and Benign Breast Disease.Asian Pacific journal of cancer prevention : APJCP · 2022Article
- Clinical and molecular evaluation of patients with ovarian cancer in the context of drug resistance to chemotherapy.Frontiers in oncology · 2022Article
- Circulating tumor cells in the early detection of human cancers.International journal of biological sciences · 2022Review
- Circulating Tumor Cell-Free DNA Genes as Prognostic Gene Signature for Platinum Resistant Ovarian Cancer Diagnosis.Biomarker insights · 2022Article
- Role of Circulating Biomarkers in Platinum-Resistant Ovarian Cancer.International journal of molecular sciences · 2021Review
- New Trends in the Detection of Gynecological Precancerous Lesions and Early-Stage Cancers.Cancers · 2021Review
- Exosomes as A Next-Generation Diagnostic and Therapeutic Tool in Prostate Cancer.International journal of molecular sciences · 2021Review
- Article
- Circulating Cell-Free DNA Methylation Profiles in the Early Detection of Ovarian Cancer: A Scoping Review of the Literature.Cancers · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Limited understanding of ovarian cancer (OC) genome portrait has hindered the therapeutic advances. The serial monitoring of tumor genotypes is becoming increasingly attainable with circulating cell-free DNA (cf-DNA) and circulating tumor cells (CTCs) emerging as "liquid biopsies". They represent non-invasive biomarkers and are viable, as they can be isolated from human plasma, serum and other body fluids. Molecular characterization of circulating tumor DNA (ct-DNA) and CTCs offer unique potentials to better understand the biology of metastasis and resistance to therapies. The liquid biopsies may also give innovative insights into the process of rapid and accurate identification, resistant genetic alterations and a real time monitoring of treatment responses. In addition, liquid biopsies are shedding light on elucidating signal pathways involved in invasiveness and metastasis competence; but the detection and molecular characterization of ct-DNA and CTCs are still challenging, since they are rare, and the amount of available samples are very limited. This review will focus on the clinical potential of ct-DNA and CTCs in both the early and advanced diagnosis, prognosis, and in the identification of resistance mutations in OC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.